Olstein Capital Management L.P. Has $5.09 Million Holdings in Hologic, Inc. (HOLX)

Olstein Capital Management L.P. decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 23.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 128,000 shares of the medical equipment provider’s stock after selling 39,700 shares during the quarter. Olstein Capital Management L.P.’s holdings in Hologic were worth $5,088,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in HOLX. Parnassus Investments CA increased its position in shares of Hologic by 3.4% during the second quarter. Parnassus Investments CA now owns 16,241,334 shares of the medical equipment provider’s stock valued at $645,593,000 after buying an additional 535,745 shares during the period. Victory Capital Management Inc. increased its position in shares of Hologic by 5.1% during the second quarter. Victory Capital Management Inc. now owns 5,813,464 shares of the medical equipment provider’s stock valued at $231,085,000 after buying an additional 282,510 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Hologic by 15.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,301,792 shares of the medical equipment provider’s stock valued at $85,995,000 after buying an additional 301,278 shares during the period. Guggenheim Capital LLC increased its position in shares of Hologic by 4.7% during the first quarter. Guggenheim Capital LLC now owns 1,739,642 shares of the medical equipment provider’s stock valued at $64,993,000 after buying an additional 77,589 shares during the period. Finally, Amundi Pioneer Asset Management Inc. increased its position in shares of Hologic by 818.9% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 1,521,695 shares of the medical equipment provider’s stock valued at $56,851,000 after buying an additional 1,356,091 shares during the period. Hedge funds and other institutional investors own 93.34% of the company’s stock.

Several equities analysts recently issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $50.00 price target on shares of Hologic in a research report on Wednesday, August 1st. Canaccord Genuity reduced their price target on shares of Hologic from $42.00 to $41.00 and set a “hold” rating on the stock in a research report on Tuesday, August 14th. Barclays reduced their price target on shares of Hologic from $54.00 to $50.00 and set an “overweight” rating on the stock in a research report on Thursday, May 3rd. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a research report on Friday, May 25th. Finally, BTIG Research reiterated a “buy” rating and set a $44.00 price target on shares of Hologic in a research report on Sunday, May 6th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $45.33.

In related news, insider Peter J. Valenti III sold 10,107 shares of the business’s stock in a transaction dated Tuesday, May 29th. The shares were sold at an average price of $38.52, for a total transaction of $389,321.64. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.88% of the company’s stock.

NASDAQ:HOLX opened at $38.26 on Tuesday. Hologic, Inc. has a one year low of $35.10 and a one year high of $45.09. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29. The stock has a market cap of $10.43 billion, a P/E ratio of 18.85, a price-to-earnings-growth ratio of 1.75 and a beta of 0.74.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, topping the consensus estimate of $0.56 by $0.02. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. The business had revenue of $824.00 million for the quarter, compared to analyst estimates of $800.14 million. research analysts anticipate that Hologic, Inc. will post 2.24 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: Trading Penny Stocks

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply